To include your compound in the COVID-19 Resource Center, submit it here.

ParvOryx: Phase I/IIa started

Oryx began an open-label, dose-escalation, German Phase I/IIa trial to

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE